Medicare beneficiaries still face huge out-of-pocket expenses because of uncapped cost sharing in the catastrophic coverage phase. This is especially true for beneficiaries who take specialty drugs.
One of the primary goals of the Affordable Care Act is to reduce the out-of-pocket (OOP) spending for prescription drugs for Medicare beneficiaries. This spending was to be reduced by narrowing the gap between the initial coverage limit and the catastrophic coverage threshold. However, new research in Health Affairs found that these beneficiaries still face huge OOP expenses because of uncapped cost sharing in the catastrophic coverage phase. This is especially true for Medicare beneficiaries who take specialty drugs.
Health policies have repeatedly focused on making high-cost drugs more affordable to those who need them. Hence, the introduction of the Medicare prescription drug benefit (Medicare Part D). However, the problem of affordability still remained because of the “doughnut hole”—a significant gap in coverage between the initial coverage limit and the catastrophic coverage threshold. Due to this hole, many beneficiaries/seniors have to incur huge OOP expenses because they end up paying the full cost of prescription drugs.
“The issue is exacerbated by the persistence of high spending among specialty drug users,” the authors wrote. “A growing body of evidence also suggests that higher patient cost sharing for specialty drugs is associated with reductions in use, which raises concerns related to patient adherence and potentially broader effects on patients’ health and other medical spending.”
Study Design & Results
Using the pharmacy claims from a nationally representative 20% random sample of Medicare beneficiaries between 2008 and 2012, the researchers analyzed trends in total and OOP spending among Medicare beneficiaries who take at least 1 high-cost specialty drug from the top 8 specialty drug classes in terms of spending. Additionally, only beneficiaries who took specialty drugs for treating multiple sclerosis and rheumatoid arthritis were assessed for when they reached the catastrophic coverage threshold, since these 2 drug classes had a relatively larger patient population.
In general, during the study period, the annual total drug spending per specialty drug user increased from $18,335 to $33,301. Consequently, the proportion of expenditures incurred while in the catastrophic coverage phase increased from 70% to 80%.
For the 2 chronic condition—multiple sclerosis and rheumatoid arthritis—beneficiaries taking specialty drugs reached the catastrophic coverage threshold by the end of the study period. For multiple sclerosis, 96% patients and for rheumatoid arthritis, 86% patients reached the catastrophic coverage threshold at an accelerated level.
Implementing Limits on Patients’ OOP Costs
Beginning 2016, once a beneficiary has reached $4850 in OOP spending, he or she transitions from the doughnut hole phase to the catastrophic coverage phase. This means that the beneficiary pays 5% of the purchase price of covered prescription drugs for the remainder of the year (insurance pays 15% and a federal reinsurance program pays the remaining 80%). Even though 5% may seem less, for patients who depend on these specialty drugs for a long duration, it represents a considerable OOP burden for them. The rising prices for the drugs only add to the woes.
“We believe that policy makers should consider implementing policies that limit seniors’ out-of- pocket liability for prescription drug expenditures, as has recently been implemented in other insurance markets,” the authors concluded. “A proposal implementing a catastrophic coverage cap on annual out-of-pocket spending for pharmaceuticals among beneficiaries enrolled in Part D should be considered as well.”
California Aims for Equity by Redefining Cancer Care
December 8th 2023Authors highlight key aspects of the California Cancer Care Equity Act, including its focus on Medi-Cal beneficiaries, the requirement for managed care plans to contract with specialized cancer centers, and the definition of complex cancers.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
What We’re Reading: RSV Vaccine Demand; Permanent Contraception; Drug Negotiation Impact
December 8th 2023The Biden administration recently met with manufacturers of respiratory syncytial virus (RSV) immunizations to encourage them to increase access to the vaccine; since the Dobbs v Jackson decision, many patients have been seeking more permanent reproductive health care solutions; a Mathematica analysis showed that Medicare prescription drug price negotiations could have cut seniors’ out-of-pocket costs by nearly a quarter had the program been in effect in 2021.
Read More
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
Research Reveals the Role of Structural Racism in Lung Cancer Risk
December 7th 2023Spanning 22 studies, the analysis illuminated housing disparities, occupational hazards, unequal health care access, economic inequality, and discriminatory industry practices and how they collectively contribute to heightened lung cancer risks.
Read More